

on the other side. Should this case be considered pT2c? In this particular example what should be a minimum extent for a case to be considered bilateral? During the consensus conference there was no consensus regarding definition of index tumor, and the minimum size for a second tumor to be considered for the whole case to be classified as pT2c.

Overview of the literature indicates that current pathological T2 substaging criteria lack clinical relevance and the majority of conference attendees wished to discontinue pT2 substaging. Therefore, the consensus was that reporting of pathological T2 substages should, at present, be optional.

References

1. International Union Against Cancer (UICC). TNM Classification of malignant tumours, 7th ed, Sobin LH, Gospodarowicz M, Wittekind Ch (eds). Geneva:Wiley-Blackwell, 2009, pp. 243-8.
2. Eichelberger LE, Cheng L: Does pT2b prostate carcinoma exist? Critical appraisal of the 2002 TNM classification of prostate carcinoma. *Cancer*. 2004; 100: 2573-6.
3. Quintal MM, Magna LA, Guimaraes MS, Ruano T, Ferreira U, Billis A: Prostate cancer pathologic stage pT2b (2002 TNM staging system): does it exist? *Int Braz J Urol*. 2006; 32: 43-7.
4. van der Kwast TH: Substaging pathologically organ confined (pT2) prostate cancer: an exercise in futility? *Eur Urol*. 2006; 49: 209-11.
5. Arora R, Koch MO, Eble JN, Ulbright TM, Li L, Cheng L: Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. *Cancer*. 2004; 100: 2362-6.
6. Wise AM, Stamey TA, McNeal JE, Clayton JL: Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. *Urology*. 2002; 60: 264-9.

Dr. Athanase Billis

Full-Professor of Pathology

State University of Campinas, Unicamp

Campinas, São Paulo, Brazil

E-mail: athanase@fcm.unicamp.br

RECONSTRUCTIVE UROLOGY

doi: 10.1590/S1677-55382010000500022

The use of uroflowmetry to diagnose recurrent stricture after urethral reconstructive surgery

Erickson BA, Breyer BN, McAninch JW

Department of Urology, University of California-San Francisco, San Francisco, California, USA

J Urol. 2010; 184: 1386-90

Purpose: The ability of uroflowmetry to diagnose recurrent stricture disease after urethroplasty has not been fully investigated.

Materials and Methods: Our routine post-urethroplasty monitoring includes retrograde urethrogram and voiding cystourethrogram at 3 and 12 months, in addition to uroflowmetry at 3-month intervals for a year. All uroflowmetry data, including maximum flow rate, voided volume and voiding curve shape, as well as retrograde urethrogram/voiding cystourethrogram and voiding symptom data are stored in a prospectively maintained urethroplasty database that was analyzed for patients with postoperative retrograde urethrogram/voiding cystourethrogram and satisfactory uroflowmetry in the same period. Uroflowmetry data points and urinary symptoms

were compared with corresponding findings on retrograde urethrogram/voiding cystourethrogram to determine the ability of uroflowmetry to predict recurrence.

Results: A total of 278 men (68%) met study inclusion criteria, of whom 63 (23%) had recurrent stricture. Using a maximum flow rate of less than 10 mL per second resulted in only 54% test sensitivity to predict recurrence. The highest sensitivity and negative predictive value (each 99%) were achieved when all men with symptoms and/or obstructed flow curves were evaluated. Symptoms alone had a high specificity (87%), sensitivity (88%) and negative predictive value (95%).

Conclusions: Uroflowmetry is an adequate test to screen for postoperative stricture recurrence but only when the voiding curve and urinary symptoms are also evaluated. The flow rate alone does not appear to be a reliable tool to evaluate stricture recurrence.

doi: 10.1590/S1677-55382010000500023

A simplified protocol for evaluating and monitoring urethral stricture patients minimizes cost without compromising patient outcome

Okorie CO, Pisters LL, Ndasi HT, Fekadu A

Pan-African Academy of Christian Surgeons at Banso Baptist Hospital, Kumbo, NWP, Cameroon

Trop Doct. 2010; 40: 134-7

Abstract: Uroflowmetry, urethrocystoscopy and urethrography are either not readily available or the cost is prohibitive for many patients in low-resource countries. This paper examines the use of clinical history in post-urethroplasty follow-up. We retrospectively reviewed the outcome of 54 post-urethroplasty patients. Pre-operative diagnostic work-up included simple blood tests and a retrograde urethrography, and postoperatively we did not perform any immediate diagnostic work-up. Follow-up of these patients was done through mobile phone calls and personal contacts. Eighty-nine per cent of our patients reported acceptable voiding over a mean follow-up period of 48.4 months - 79.6% were followed using mobile phone contact. In the majority of the urethral strictures cases, diagnostic work up can be kept to a minimum, thereby reducing cost. Follow-up can be done via phone calls and personal contact in many African countries where compliance is frequently less than encouraging. The spread of mobile phone networks across the continent has been remarkable.

Editorial Comment

The study by Erickson et al. seeks to arrive at a non-invasive means of predicting urethral stricture recurrence after urethroplasty. Uroflowmetry is attractive in that it is an objective test. The authors state that maximum urinary flow rate is not by itself a very good predictor of failure but that the combination of maximum flow rate, voiding pattern and urinary obstructive symptoms is predictive. Indeed, the combination of these three factors was the most predictive of a man having a recurrence (PPV 90%); yet this combination misses half the strictures (sensitivity 51%). This low sensitivity means few physicians would be inclined to forgo more invasive testing in any man. Although it was the goal of the authors to find a predictive tool, what would be more helpful to the patient would be a screening tool. A good screening tool helps a portion of the population avoid advanced confirmatory testing, while still preserving high sensitivity. With the latter goal in mind, a high threshold for maximum urinary flow rate (< 20 cc/sec) has excellent sensitivity (92%) and NPV (96%), meaning that it captures 92% of strictures and only misses 4%. While PPV is low (48%) this is acceptable as a screening tool - it just means that a little more than half of men who undergo RUG/VCUG will have no recurrent stricture. At the same time, more than half of the population in this study could avoid a RUG/VCUG because their flow rates were over 20 cc/sec - this is the proper role of a screening tool.

The goal of identifying a useful screening tool for urethral stricture recurrence is echoed in the second article, by Okorie et al. They describe using mobile phones to survey urinary symptoms after urethral stricture treatment. Although the symptoms reported over the telephone were not validated objectively, the concept of telephone follow-up is important, especially in areas of the world where travel to a referral center is difficult. Others have previously shown that home measurement of timed urinary flow correlates well with office-measured maximum urinary flow rate (1). If we were able to validate a means of screening patients over the telephone with timed urinary flow rates with or without telephone-administered validated questionnaires we could spare many patients the travel to a referral center for continued follow-up.

Reference

1. Bloom DA, Foster WD, McLeod DG, Mittemeyer BT, Stutzman RE: Cost-effective uroflowmetry in men. *J Urol.* 1985; 133: 421-4.

Dr. Sean P. Elliott

*Department of Urology Surgery
University of Minnesota
Minneapolis, Minnesota, USA
E-mail: selliot@umn.edu*

UROLOGICAL ONCOLOGY

doi: 10.1590/S1677-55382010000500024

Should bladder cuff excision remain the standard of care at nephroureterectomy in patients with urothelial carcinoma of the renal pelvis? A population-based study

Lughezzani G, Sun M, Perrotte P, Shariat SF, Jeldres C, Budaus L, Alasker A, Duclos A, Widmer H, Latour M, Guazzoni G, Montorsi F, Karakiewicz PI

Cancer Prognosis and Health Outcomes Unit, University of Montreal Health Center, Montreal, Québec, Canada; Department of Urology, Vita-Salute San Raffaele University, Milan, Italy

Eur. Urol. 57: 956-962, 2010

Background: A large, multi-institutional, tertiary care center study suggested no benefit from bladder cuff excision (BCE) at nephroureterectomy in patients with upper tract urothelial carcinoma (UC).

Objective: We tested and quantified the prognostic impact of BCE at nephroureterectomy on cancer-specific mortality (CSM) in a large population-based cohort of patients with UC of the renal pelvis.

Design, Setting, And Participants: A cohort of 4210 patients with UC of the renal pelvis were treated with nephroureterectomy with (NUC) or without (NU) a BCE between 1988 and 2006 within 17 Surveillance, Epidemiology, and End Results registries.

Measurements: Cumulative incidence plots and competing risks regression models compared CSM after either NUC or NU. Covariates consisted of pathologic T and N stages, grade, age, year of surgery, gender, and race.

Results and Limitations: Respectively, 2492 (59.2%) and 1718 (40.8%) patients underwent a nephroureterectomy with or without BCE. In univariable and multivariable analyses, BCE omission increased CSM rates in patients with pT3N0/x, pT4N0/x, and pT(any)N1-3 UC of the renal pelvis. For example, in patients with pT3N0/x disease, holding all other variables constant, BCE omission increased CSM in a 1.25-fold fashion